2162.HK
Price:
$42.25
Market Cap:
$10.39B
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat...[Read more]
Industry
Biotechnology
IPO Date
2021-07-08
Stock Exchange
HKSE
Ticker
2162.HK
According to Keymed Biosciences Inc.’s latest financial reports and current stock price. The company's current ROE is -20.16%. This represents a change of 150.46% compared to the average of -8.05% of the last 4 quarters.
The mean historical ROE of Keymed Biosciences Inc. over the last ten years is -1.69%. The current -20.16% ROE has changed 1.09% with respect to the historical average. Over the past ten years (40 quarters), 2162.HK's ROE was at its highest in in the June 2021 quarter at 78.48%. The ROE was at its lowest in in the December 2023 quarter at -13.61%.
Average
-1.69%
Median
-10.63%
Minimum
-106.78%
Maximum
76.08%
Discovering the peaks and valleys of Keymed Biosciences Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 73.03%
Maximum Annual ROE = 76.08%
Minimum Annual Increase = -240.35%
Minimum Annual ROE = -106.78%
Year | ROE | Change |
---|---|---|
2024 | -20.82% | 73.03% |
2023 | -12.03% | 30.46% |
2022 | -9.22% | -91.36% |
2021 | -106.78% | -240.35% |
2020 | 76.08% | 21.48% |
The current ROE of Keymed Biosciences Inc. (2162.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14.03%
5-year avg
-14.56%
10-year avg
-1.69%
Keymed Biosciences Inc.’s ROE is less than CARsgen Therapeutics Holdings Limited (0%), greater than Brii Biosciences Limited (-18.42%), less than Zylox-Tonbridge Medical Technology Co., Ltd. (3.23%), less than Simcere Pharmaceutical Group Limited (10.49%), less than Medlive Technology Co., Ltd. (6.65%),
Company | ROE | Market cap |
---|---|---|
0% | $8.82B | |
-18.42% | $1.46B | |
3.23% | $5.85B | |
10.49% | $21.21B | |
6.65% | $8.87B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Keymed Biosciences Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Keymed Biosciences Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Keymed Biosciences Inc.'s ROE?
How is the ROE calculated for Keymed Biosciences Inc. (2162.HK)?
What is the highest ROE for Keymed Biosciences Inc. (2162.HK)?
What is the 3-year average ROE for Keymed Biosciences Inc. (2162.HK)?
What is the 5-year average ROE for Keymed Biosciences Inc. (2162.HK)?
How does the current ROE for Keymed Biosciences Inc. (2162.HK) compare to its historical average?